Year: 2021

– Data Presented Shows Novel Bispecific IgM Antibody is Active in Heavily Pre-treated Patients with Relapsed/Refractory NHL, including DLBCL and FL, and has a Favorable Safety Profile – – Phase 2 Clinical Trials in DLBCL and FL and Combination Clinical Trials to be Initiated –   – Company to Host Conference Call and Webcast Today at 7:30 p.m. EST – MOUNTAIN VIEW, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the presentation of clinical results from the Company’s Phase 1 trial evaluating IGM-2323, a novel bispecific IgM antibody targeting CD20 x CD3, at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. The data was featured...

Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1Median follow-up of approximately 17 months from the ELARA study showed a 67% one-year progression-free survival (PFS) rate in patients with r/r FL; for those who had a complete response, 12-month PFS was 86%1Remarkable safety profile remained consistent with initial analysis; no high-grade cytokine release syndrome was reported within eight weeks post-infusion and no new safety signals were identified1Basel, December 11, 2021 — Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular lymphoma (FL) based on a subgroup analysis from an approximately 17-month median follow-up of the pivotal Phase...

At SkiStar AB (publ)’s annual general meeting, held in Sälen on 11 December 2021, the following decisions were made.A dividend of SEK 1.50 per share was adopted. Record day 14 December 2021. Lena Apler, Sara Karlsson, Fredrik Paulsson, Gunilla Rudebjer and Anders Sundström were re-elected to the board and Anders Svensson and Vegard Søraunet were elected new members of the board. Anders Sundström was elected chairman of the board. Board fees, including committee fees, were raised to a total of SEK 2,410,000 (2020: SEK 1,900,000). The fees shall be distributed as follows: SEK 550,000 (550,000) to the chairman of the board and SEK 250,000 (220,000) each to the other non-executive directors. Audit committee members will receive total fees of SEK 240,000 (200,000), distributed as follows: SEK 120,000 (100,000) to the committee chairman and...

Cellectis’ Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab (FCA) with no Dose-Limiting Toxicities in BALLI-01 Phase 1 Study The addition of Alemtuzumab to FC (FCA) Resulted in Prolonged Host-Lymphocyte Suppression, and UCART22 Expansion Preliminary Data Demonstrating Encouraging Anti-Leukemic Activity was Observed in 2 Patients BALLI-01 is Currently Enrolling at Dose Level Three with FCA (fludarabine, cyclophosphamide, alemtuzumab) Lymphodepletion Regimen Pre-Clinical Data from Cellectis’ Proprietary Product Candidate Talglobin01 Demonstrates that TALEN® Could Be Specific and Efficient at Correcting the Mutated Beta-Globin Gene that Causes Sickle Cell DiseaseNEW YORK, Dec. 11, 2021 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq:...

Press release   Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that in excess of 94 % of the Company’s shareholders have accepted the Share Swap Offer, announced on November 24 and expired on December 9, pending final reconciliation. Considering the very high acceptance rate, the Board of Directors has as of today resolved to complete the Share Swap Offer. Moreover, based on the very high acceptance rate, the Company’s Board of Directors has resolved to apply for a delisting of the Company’s shares from Nasdaq First North Growth Market Sweden (“Nasdaq First North”) in connection the change of marketplace related to the Company’s recapitalization and reorganization (“Recapitalization”) into a U.S. holding company (Allarity Therapeutics, Inc., a Delaware corporation) and...

Press Release Stockholm, Sweden, December 11, 2021 Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021 Immunicum AB (“Immunicum”, publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, today will present positive data from its ADVANCE II Phase II study at the 63rd American Society of Hematology (ASH) Annual Meeting being held in Atlanta, Georgia from December 11-14, 2021. The Phase II data demonstrate the ability of DCP-001 to convert or significantly reduce detectable minimal residual disease (MRD) in acute myeloid leukemia (AML) patients, with fully converted patients demonstrating greater overall survival. The results of the trial also reinforced data from a preceding Phase I trial...

Figure 1Refractory Patients’ Serum IgM Levels After Treatment with Mavorixafor + Ibrutinib vs. Ibrutinib Monotherapy With or Without CXCR4 Mutations– CXCR4 antagonism proof of concept established, with 100% overall response rate to combination treatment in frontline and refractory patients – – Median Serum IgM reductions in refractory CXCR4MUT patients on combination therapy similar to those seen in CXCR4WT patients on ibrutinib monotherapy – – Study enrollment ongoing at highest dose of mavorixafor; longer-term response data, dose selection, and regulatory updates expected in 2022 – BOSTON, Dec. 11, 2021 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with...

Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma Tolerable safety profile with cytokine release syndrome (all Grade 1 or 2) observed in 9 of 37 patients (24%) Patient enrollment and dose escalation is ongoing to define the RP2D and MTD Management to host webcast and conference call to review the HPN217 data presented at ASH and provide a pipeline update on Monday, December 13, 2021 at time 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a poster with interim data from the ongoing dose-escalation portion of the Phase 1/2...

Results to be presented for the first time show mosunetuzumab induces high and durable complete response rates in people with follicular lymphoma who have received two or more prior therapies1 New efficacy data from Roche’s portfolio of cancer immunotherapies demonstrate potential of bispecific antibodies to expand upon current treatment options across several blood cancersBasel, 11 December 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new pivotal data on its CD20xCD3 T-cell engaging bispecific antibody, mosunetuzumab, will be presented for the first time at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021. Emerging data continue to show the promising benefit-risk profile of mosunetuzumab in relapsed or refractory (R/R) follicular lymphoma (FL), a slow-growing,...

The Supervisory Board of Admiral Markets AS decided to extend the term of office of Sergei Bogatenkov as the Chairman of the Management Board of Admiral Markets AS. His current mandate has been valid until December 18, 2021, now the term of office is extended for three years, valid until December 19, 2024. Further information:  Kaia Gil Communication Manager of Admiral Markets AS kaia.gil@admiralmarkets.com +372 53 413 764